Literature DB >> 11127193

Proposed standard nomenclature for new tumor necrosis factor family members involved in the regulation of bone resorption. The American Society for Bone and Mineral Research President's Committee on Nomenclature.

.   

Abstract

Recently, three new family members of the tumor necrosis factor (TNF) ligand and receptor signaling system that play a critical role in the regulation of bone resorption have been identified and cloned. These also have been shown to play an important role in regulating the immune system. A proliferation of synonyms for these molecules has led to miscommunication and redundancy. To resolve this, the President of the American Society for Bone and Mineral Research (ASBMR) appointed a special committee to recommend a standard nomenclature. After considerable deliberation and after vetting by workers in the field, the Committee recommends the names of receptor activator of NF-kappaB (RANK) for the membrane receptor, RANK ligand (RANKL) for the ligand, and osteoprotegerin (OPG) for the decoy receptor.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11127193     DOI: 10.1359/jbmr.2000.15.12.2293

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  23 in total

1.  Osteoclast-derived IGF1 is required for pagetic lesion formation in vivo.

Authors:  Kazuaki Miyagawa; Yasuhisa Ohata; Jesus Delgado-Calle; Jumpei Teramachi; Hua Zhou; David D Dempster; Mark A Subler; Jolene J Windle; John M Chirgwin; G David Roodman; Noriyoshi Kurihara
Journal:  JCI Insight       Date:  2020-03-26

Review 2.  Harnessing the versatile role of OPG in bone oncology: counterbalancing RANKL and TRAIL signaling and beyond.

Authors:  Maria V Deligiorgi; Mihalis I Panayiotidis; John Griniatsos; Dimitrios T Trafalis
Journal:  Clin Exp Metastasis       Date:  2019-10-01       Impact factor: 5.150

Review 3.  Cytokines and chemokines involved in the defense reaction against HIV-1 and hepatitis B virus: isn't it time to use a standardized nomenclature of the involved mediators?

Authors:  Lutz G Gürtler
Journal:  Virus Genes       Date:  2019-12-17       Impact factor: 2.332

4.  Mutation of the sequestosome 1 (p62) gene increases osteoclastogenesis but does not induce Paget disease.

Authors:  Noriyoshi Kurihara; Yuko Hiruma; Hua Zhou; Mark A Subler; David W Dempster; Frederick R Singer; Sakamuri V Reddy; Helen E Gruber; Jolene J Windle; G David Roodman
Journal:  J Clin Invest       Date:  2006-12-21       Impact factor: 14.808

Review 5.  Control of bone development by P2X and P2Y receptors expressed in mesenchymal and hematopoietic cells.

Authors:  Lisa Y Lenertz; Cory J Baughman; Noelle V Waldschmidt; Roman Thaler; Andre J van Wijnen
Journal:  Gene       Date:  2015-06-14       Impact factor: 3.688

Review 6.  Osteoblast-osteoclast interactions.

Authors:  Xiao Chen; Zhongqiu Wang; Na Duan; Guoying Zhu; Edward M Schwarz; Chao Xie
Journal:  Connect Tissue Res       Date:  2017-03-21       Impact factor: 3.417

Review 7.  Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab.

Authors:  David L Lacey; William J Boyle; W Scott Simonet; Paul J Kostenuik; William C Dougall; John K Sullivan; Javier San Martin; Roger Dansey
Journal:  Nat Rev Drug Discov       Date:  2012-05       Impact factor: 84.694

8.  A SQSTM1/p62 mutation linked to Paget's disease increases the osteoclastogenic potential of the bone microenvironment.

Authors:  Yuko Hiruma; Noriyoshi Kurihara; Mark A Subler; Hua Zhou; Christina S Boykin; Heju Zhang; Seiichi Ishizuka; David W Dempster; G David Roodman; Jolene J Windle
Journal:  Hum Mol Genet       Date:  2008-09-02       Impact factor: 6.150

9.  The RANKL/RANK/OPG pathway.

Authors:  Brendan F Boyce; Lianping Xing
Journal:  Curr Osteoporos Rep       Date:  2007-09       Impact factor: 5.096

Review 10.  RANKL, a necessary chance for clinical application to osteoporosis and cancer-related bone diseases.

Authors:  Hisataka Yasuda
Journal:  World J Orthop       Date:  2013-10-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.